Fg. Soriano et al., Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase, CIRCUL RES, 89(8), 2001, pp. 684-691
Oxygen- and nitrogen-derived free radicals and oxidants play an important r
ole in the pathogenesis of diabetic endothelial dysfunction. Recently we pr
oposed the importance of oxidant-induced DNA strand breakage and activation
of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) in the pathogenes
is of diabetic endothelial dysfunction. In this study, we tested whether es
tablished diabetic endothelial dysfunction is reversible by PARP inhibition
. The novel PARP inhibitor PJ34 (10 mg/kg per day PO) was given at various
lengths (4 weeks or 3 days) for established streptozotocin-diabetic animals
. In addition, we also tested whether incubation of the aortic rings with P
J34 (3 mu mol/L) or a variety of other PARP inhibitors for 1 hour affects t
he diabetic vascular changes. Both 4-week and 3-day PARP-inhibitor treatmen
t of streptozotocin-diabetic mice with established endothelial dysfunction
fully reversed the acetylcholine-induced endothelium-dependent relaxations
in vitro. Furthermore, 1-hour in vitro incubation of aortae from streptozot
ocin-diabetic mice with various PARP inhibitors was able to reverse the end
othelial dysfunction. ATP, NAD(+), and NADPH levels were markedly reduced i
n diabetic animals, and PARP-inhibitor treatment was able to restore these
alterations. Unexpectedly, pharmacological inhibition of PARP not only prev
ents the development of the endothelial dysfunction but is also able to rap
idly reverse it. Thus, PARP activation and the associated metabolic comprom
ise represent an ongoing process in diabetic blood vessels. Pharmacological
inhibition of this process is able to reverse diabetic endothelial dysfunc
tion.